{"id":"NCT00829829","sponsor":"Regeneron Pharmaceuticals","briefTitle":"PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-05","completion":"2010-06","firstPosted":"2009-01-27","resultsPosted":"2017-04-28","lastUpdate":"2017-04-28"},"enrollment":241,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Intercritical Gout"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rilonacept 80 mg","otherNames":[]},{"type":"DRUG","name":"Rilonacept 160 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rilonacept 80 mg","type":"ACTIVE_COMPARATOR"},{"label":"Rilonacept 160 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.","primaryOutcome":{"measure":"Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)","timeFrame":"Day 1 to Day 112 (Week 16)","effectByArm":[{"arm":"Placebo","deltaMin":1.06,"sd":1.59},{"arm":"Rilonacept 80 mg","deltaMin":0.29,"sd":0.77},{"arm":"Rilonacept 160 mg","deltaMin":0.21,"sd":0.54}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":91,"countries":["United States","Canada"]},"refs":{"pmids":["22549879"],"seeAlso":["http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=501081761&QV1=RILONACEPT","http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=000315300&QV1=ALLOPURINOL","http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=017795210&QV1=ALLOPURINOL+SODIUM"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":79},"commonTop":["Upper respiratory tract infection","Pain in extremity","Headache","Injection site erythema","Injection site reaction"]}}